Blog

  • Exclusive Networks North America Signs with A10 Networks to Expand Cybersecurity Capabilities

    Exclusive Networks North America Signs with A10 Networks to Expand Cybersecurity Capabilities

    FREMONT, CA / ACCESS Newswire / July 23, 2025 / Exclusive Networks, a global leader in cybersecurity, has established a North American distribution agreement with A10 Networks that will magnify the reach of the distributor’s security and infrastructure solutions for on-premises, hybrid cloud and edge-cloud environments.

    “We place a high value on organizations that can effectively support our missions in both cybersecurity and the channel, and Exclusive Networks excels in both areas,” says Phil Labas, RVP, Americas channel and alliance partners at A10 Networks. “This relationship will expand our reseller base, education and marketing abilities, and collective technical expertise, as well as support strategic use cases in security and AI across the enterprise market.”

    This new arrangement allows solution providers to procure A10 Networks’ products and services in the United States and Canada through the Exclusive Networks’ growing community. A10’s specialized network, application and AI security solutions target mid-market to enterprise organizations, including global enterprises, service providers, federal agencies, and public sector institutions. The A10 Networks solutions are designed to support customers with complex networking, security, and application delivery requirements-such as DDoS protection, SSL inspection, CGNAT, NG-WAF, API and bot protection, and AI-ready high-performance load balancing.

    “MSPs, VARs, solution providers and systems integrators are seeking more advanced cybersecurity tools to protect their clients and themselves from the rising threats, and our new relationship with A10 Networks will simplify that process,” says Andrew Warren, Vice President of Sales & Marketing for Exclusive Networks, North America. “This agreement is consistent with our commitment to offering the most comprehensive network, application and AI security solutions to our partners and, ultimately, their clients. We anticipate A10 Networks will bring a wealth of new sales and support opportunities to all the skilled IT and cybersecurity professionals in the Exclusive Networks community.”

    Key advantages of this agreement for the community include:

    • More advanced and highly comprehensive network, application and AI security capabilities

    • Simplified procurement through Exclusive Networks

    The addition of A10 Networks to Exclusive Networks’ line card is part of a larger initiative to expand the distributor’s capabilities and presence in North America. This includes major additions to its North American leadership team, and revitalized investments in consultative services and offerings that go beyond traditional legacy distribution offerings. The objective is to support resellers and end users in the most practical and urgent ways possible, helping them grow and thrive.

    For more information or help ordering these technologies, contact your Exclusive Networks North American account management team.

    About Exclusive Networks
    Exclusive Networks is a global cybersecurity go-to-market specialist that provides partners and end-customers with a wide range of services and product portfolios via proven routes to market. With offices in over 45 countries and the ability to serve customers in over 170 countries, we combine a local perspective with the scale and delivery of a single global organization.

    Our best-in-class vendor portfolio is carefully curated with all leading industry players. Our services range from managed security to specialist technical accreditation and training and capitalize on rapidly evolving technologies and changing business models. For more information visit https://www.exclusive-networks.com/usa/.

    # # #

    The A10 logo and A10 Networks are trademarks or registered trademarks of A10 Networks, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.

    FOR MORE INFORMATION, CONTACT:
    Suzanne Mattaboni, CommCentric (on behalf of Exclusive Networks)
    smattaboni@commcentric.com

    SOURCE: Exclusive Networks USA

    View the original press release on ACCESS Newswire

  • Vista Institute Launches, Revolutionizing Education for Plaintiff Law Firms

    Vista Institute Launches, Revolutionizing Education for Plaintiff Law Firms

    BATON ROUGE, LA / ACCESS Newswire / July 23, 2025 / Vista Consulting has officially unveiled Vista Institute, a groundbreaking online education platform designed exclusively for plaintiff law firms. This innovative platform addresses a critical need for on-demand, customized learning that helps law firms optimize operations, enhance team performance, and drive growth.

    Vista Consulting Team- Vista Institute
    Vista Consulting Team- Vista Institute
    Vista Institute Logo

    The launch comes after decades of observing significant gaps in the marketplace for tailored legal education. Many small to mid-sized plaintiff law firms struggle to access industry-specific resources that support continuing education and operational improvement. Vista recognized this challenge and set out to create a solution that combines flexibility, expertise, and transformative insights.

    “Our work with firms revealed a common theme,” said Mary Ellen Murrah, Chief Strategy & Marketing Officer of Vista Consulting. “Plaintiff law firms need education resources that are practical, relevant, and adaptable to their unique challenges. Vista Institute is our answer to this demand: a platform built to empower firms to thrive in an increasingly competitive industry.”

    Custom Learning, Anytime and Anywhere
    Unlike traditional training programs, Vista Institute delivers a fully customizable learning experience. The platform offers a wide range of courses designed to tackle critical areas for plaintiff law firms such as client intake, case management, reporting, leadership, and marketing. Firms can access content on-demand, allowing team members to learn at their own pace and test their knowledge without disrupting daily operations.

    Key features include:

    • Expert-led video courses and modules.

    • Downloadable resources and role-specific training paths.

    • Interactive quizzes to reinforce learning.

    Increasing Efficiency and Driving Results
    At its core, Vista Institute is a business growth tool. Each course is designed to deliver strategies that lead to measurable outcomes. For example, firms looking to improve their intake process can follow step-by-step guidance to optimize lead conversion, while leadership courses focus on building stronger, more cohesive teams.

    Early adopters of the platform have reported noticeable improvements. Tina Jones, Office Manager and Marketing Director for Long & Long Attorneys, said, “Vista Institute has been my ultimate survival guide. Having their expert knowledge at my fingertips has completely transformed how I lead my law firm. From accounting and HR to data analysis and talent acquisition, every critical piece of running a successful practice is just a click away. The post-presentation Q&As are pure gold, providing actionable insights I can implement immediately. Thanks to Vista Institute, I’ve not only streamlined my operations, but also elevated my ability to lead with confidence and clarity. It’s like having the ultimate roadmap to managing a thriving plaintiff law firm.”

    Transforming the Education Landscape for Law Firms
    The introduction of Vista Institute marks a shift in how plaintiff law firms approach continuing education. By offering a platform that emphasizes customization, accessibility, and measurable results, Vista aims to set a new standard in the legal industry.

    “Law firms need more than generic advice and outdated training tools,” added Vista’s CEO Tim McKey. “They need resources that reflect the unique dynamics of plaintiff law practice. Vista Institute delivers exactly that.”

    About Vista Consulting
    Vista Consulting specializes in helping plaintiff law firms optimize their operations and achieve greater success. With decades of industry experience, Vista has become a trusted partner for firms seeking data-driven solutions and practical operations guidance.

    For more information about Vista Institute and how to get started, visit https://vistainstitute.vistact.com/

    Contact Information
    Don Pursell
    Principal
    dpursell@cimmp.com
    702-944-2464

    .

    SOURCE: Vista Consulting Team

    View the original press release on ACCESS Newswire

  • Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

    Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

    Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date

    FRAMINGHAM, MA / ACCESS Newswire / July 23, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has continued its collaboration with The Scripps Research Institute (“TSRI”) to advance the development of the Company’s development program evaluating the combination of systemic DNase I and CAR T-cell therapies.

    Xenetic’s systemic DNase I candidate, XBIO-015, is currently in preclinical development in combination with CAR-T cell therapy for both hematologic and solid tumors. Studies conducted at TSRI using lymphoma and metastatic melanoma models have shown that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and markedly extends survival compared to CAR-T cell monotherapy. Importantly, systemic DNase I-mediated degrading of neutrophil extracellular traps (NETs) enhances CAR-T cell efficacy increasing the infiltration of both CAR-T cells and endogenous T cells into tumors and by mitigating the immunosuppressive tumor microenvironment (TME). Based on these promising results, the research program has been expanded to include additional models of lymphoma and leukemia to further validate these findings.

    “We are pleased to further expand our collaboration with Scripps Research and explore the full potential of our DNase-based oncology platform. The data generated to date continues to be encouraging and we believe provides a compelling rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR-T cell therapy. We are grateful for the Scripps Research team and look forward to continuing to leverage their knowledge and expertise,” commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.

    Xenetic’s DNase-based oncology platform is designed to target NETs, which are weblike structures composed of extracellular chromatin coated with histones and other proteins. In cancer, NETs are expelled by activated neutrophils into the TME and blood, thereby promoting cancer spread and local and systemic immunosuppression. Reduction of NETs burden via application of Xenetic’s proprietary recombinant human DNase I has been shown to improve efficacy of immunotherapy, adoptive cell therapy and chemotherapy in preclinical animal models.

    Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors.

    About Xenetic Biosciences

    Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company’s DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase I program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

    For more information, please visit the Company’s website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

    Forward-Looking Statements

    This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “remain,” “focus”, “confidence in”, “potential”, “making”, and other words of similar meaning, including, but not limited to: continuing to leverage the knowledge and expertise of the team at Scripps to potentially expand and broaden the utility of our proprietary platform technology; and expectations regarding our DNase-based oncology platform, including statements regarding: advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications; focusing on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications; advancing the development of the Company’s program on the combination of systemic DNase and CAR T-cell therapies; our belief that preclinical data that highlights the critical role of NETs in modulating CAR-T cell efficacy provides a compelling rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR-T cell therapy; plans to advance our DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors; the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression; and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. All forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company’s reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

    Contact:

    JTC Team, LLC
    Jenene Thomas
    (908) 824-0775
    xbio@jtcir.com

    SOURCE: Xenetic Biosciences, Inc.

    View the original press release on ACCESS Newswire

  • NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

    NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

    SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains that the strong effectiveness of its broad-spectrum antiviral drug against all viruses that the drug NV-387 was tested against to date will drive significant valuation for its portfolio. The Company further elucidates that the MPox, Smallpox, and Measles indications of NV-387 are expected to enable rapid regulatory development towards approval and realization of early revenues from multiple pathways.

    As additional indications of NV-387 have been validated in animal studies, approvals against the multiple indications of NV-387 are expected to drive increase in overall market share that the Company can achieve once the drug is approved. The costs leading up to Phase II clinical trial would be substantially common across all indications of this same drug, improving return on investment significantly.

    Additionally, NV-387 should become the drug of choice to develop and stockpile for strategic pandemic preparedness and response because of its activity against most of the viruses of concern at present: Influenza, Coronaviruses, Orthopoxviruses (Smallpox and Mpox), and Measles. The Company believes that NV-387 is likely to be effective against Ebola/Marburg viruses, Hendra/Nipah viruses, and other lethal viruses as well, based on known binding of these viruses to HSPG. In addition to the USA, UK, Europe and India have established agencies to enable pandemic preparedness and response.

    Approval of NV-387 against any of the currently established indications would drive its value as a strategic tool for pandemic preparedness against a multiplicity of potential threats. Pandemic preparedness is already a multi-billlion dollar market globally, and growing, as additional countries and regions seek to fortify their public health defenses against unknown viral threats. (see further below).

    To this end, the Company is moving forward to open a Phase II clinical trial to evaluate effectiveness of NV-387 to treat MPox virus infections. If the trial is successful, NV-387 will be the first ever drug to be approved for MPox [1] . There is no effective drug for MPox at present.

    Such approval will also translate to NV-387 as a currently best available option for potential smallpox therapeutics as well, based on human infection data of the smallpoxvirus-related virus MPXV , rather than animal orthopoxvirus data that FDA has currently relied upon [1] .

    Additionally, the Company intends to file for orphan drug status for several indications of NV-387, including MPox, Smallpox, and Measles. Each orphan drug indication in itself would result in several economic benefits, in addition to increased interactions with the FDA.

    We believe some of the indications of NV-387 will be eligible for Fast-Track designation, as well as for awards of Priority Review Vouchers (PRV). A PRV is a tradable instrument that has been traded at about $150 million to $250 million dollars each because the buying pharma company can apply the PRV for any one drug to expedite its own drugs in development. Thus PRVs could enable an early revenue source for the Company if awarded.

    The speed with which a first indication of NV-387 can be approved is estimated to be the fastest for Mpox, Smallpox, and Measles. This is because of the specific orphan drug characteristics of these diseases in the USA. This is why the Company has prioritized these indications.

    The Company is continuing its work on planning of clinical trials for what are generally considered as commercially lucrative indications that include Influenza, RSV, other respiratory viruses, as well as coronaviruses.

    Viruses crossing over newly into humans from other species do so only upon acquiring significant ability to bind to HSPG, the cell-side molecule that NV-387 mimics as a decoy for the viruses [2] . It is highly unlikely that bioterrorism agents would be created that can drastically infect humans and yet do not bind to HSPG.

    To date, pandemic preparedness has been dominated by one-drug-one-bug philosophy. With hundreds of potential biothreats, such a strategy is too expensive and would not realize a highly effective protective shield against potential pandemics.

    Besides, the medical countermeasures pursued to-date for pandemic preparedness are severely lacking in that every one of them would be readily defeated by the virus as it mutates or evolves in the field. This is one lesson that has become starkly clear after the COVID-19 pandemic.

    NV-387 is expected to provide a low cost option for pandemic preparedness against a multiplicity of threats, and could become an effective first response drug for practically any viral pandemic. Over 90% of viruses that can cause disease in humans are known to bind to HSPG. Our development of NV-387 suggests that most of these viruses would be susceptible to NV-387. Moreover, escape from NV-387 is highly unlikely because even as viruses mutate or evolve, they continue to bind well to HSPG as long as they are pathogenic in humans.

    ABOUT NANOVIRICIDES

    NanoViricides, Inc. (the “Company”) ( www.nanoviricides.com ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

    The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

    Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

    The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

    This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

    The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

    FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

    Contact:
    NanoViricides, Inc.
    info@nanoviricides.com

    Public Relations Contact:
    ir@nanoviricides.com

    [1] Tecovirimat and Brincidofovir were approved by the US FDA for Smallpox therapeutics based on animal model data generated in animal infections by animal native orthpoxviruses. Tecovirimat failed in clinical trials of MPox. Brincidofovir caused sever drug-induced liver injury (DILI) in there of three patients given the drug in case studies, not in clinical trial.

    [2] It has been reported that highly pathogenic duck influenza viruses that lack or substantially lack HSPG binding ability do not cause significant pathology in other birds, nor in humans. They appear to use exclusively sialic acid-related receptors and yet have failed to infect other species. We believe these results require further investigation.

    SOURCE: NanoViricides

    View the original press release on ACCESS Newswire

  • LHH Joins the Recruitment Process Outsourcing Association to Advance the Evolution of RPO and Workforce Transformation

    LHH Joins the Recruitment Process Outsourcing Association to Advance the Evolution of RPO and Workforce Transformation

    By joining the RPOA community of leaders, LHH is taking a leading and active role in shaping the future of RPO and establishing the practice as a strategic engine for organizational agility.

    NEW YORK CITY, NY / ACCESS Newswire / July 23, 2025 / LHH, a global integrated professional talent solutions provider and global business unit of the Adecco Group, today announced its Gold Membership with the Recruitment Process Outsourcing Association (RPOA). This move underscores LHH’s commitment to advancing the RPO industry and marks a significant step in LHH‘s strategic expansion within the RPO sector, with its full offering centralized by The Adecco Group under LHH earlier this year.

    “Now that our RPO offering is fully integrated as LHH RPO, our partnership with RPOA is critical to ensure we are actively guiding the strategic evolution and new standard of RPO globally,” shared Serge Shine, Global Head of LHH RPO. “LHH is the only provider that combines flexible RPO solutions with development and career transition services, helping organizations solve talent challenges holistically. We help organizations think bigger than just filling jobs. By connecting hiring to their larger talent priorities, we make every recruitment decision count. This comprehensive approach empowers our clients to hire smarter and pivot faster.”

    “That’s not the only thing that sets LHH RPO apart.” Adds Alex Ridder, LHH RPO Head of Client Partnerships: “Talent acquisition isn’t happening in isolation anymore, that’s why we designed LHH’s RPO offering to be highly adaptable. Whether it’s scaling recruitment quickly in competitive markets, integrating new hiring tech without disrupting teams, or building talent pipelines for hard-to-fill roles, we help people make work meaningful while helping to tackle the tough challenges together. Our approach combines innovation and human centricity, with exceptional care, to deliver results that matter.”

    With 400+ experts across five continents, LHH RPO works with clients across various industries to develop and optimize their RPO strategies through a comprehensive and flexible suite of RPO solutions, backed by global reach and local knowledge, to help drive cost efficiency and transform organizations across the entire talent lifecycle.

    Earlier this year, LHH RPO was named a ‘Major Contender’ in Everest Group’s 2025 PEAK Matrix® for Global RPO Services, a milestone moment and a reflection of the impact LHH brings in rethinking talent solutions.

    “LHH joining the RPOA network supports our mission of fostering a collaborative community where RPO leaders can gather and share knowledge, transforming the future of the workforce collectively,” said Lamees Abourahma, RPOA CEO. “LHH RPO provides value to our members addressing the challenges and needs of the RPO ecosystem with unique perspectives.” She added, “We’re thrilled to recognize and support LHH’s RPO integration and market expansion and look forward to welcoming their experts to engage, learn and contribute to the evolution of the RPO industry. This is what the RPOA is all about, empowering leaders and advancing the profession.”

    For more information on LHH RPO’s offerings, visit LHH’s Guide to Recruitment Process Outsourcing or contact LHH RPO.

    ###

    About LHH

    LHH empowers professionals and organizations to achieve bold ambitions and secure lasting impact through unique advisory services and professional talent solutions.

    LHH’s full suite of offerings connects solutions that are traditionally siloed, making LHH a single talent partner for organizations. In a rapidly evolving landscape with complex challenges, we create value across the entire professional talent journey. From hiring great people, developing skills and nurturing leaders, to advancing individuals to the next stage of their careers, LHH makes talent a competitive edge.

    We believe the future of work lies at the intersection of exceptional human care and innovation. Powered by science, technology, and proprietary data analytics, LHH’s approach is crafted to align with business strategies and cultures, delivering powerful, sustainable, and measurable impact.

    LHH has a team of over 12,000 professionals, across 60+ countries, and more than 50 years of experience. As part of the Adecco Group, we bring together global excellence, local knowledge and centralized coordination for thousands of companies and millions of people worldwide.

    Recruitment. Development. Career Transition.
    LHH. A beautiful working world.

    To learn more about LHH, visit: lhh.com.

    About RPOA

    The Recruitment Process Outsourcing Association (RPOA) is a member-driven, mission-driven organization committed to advancing, elevating, and promoting recruitment process outsourcing as a strategic talent solution. We strive to nurture a collaborative community, create thought leadership, and educate the marketplace about recruitment process outsourcing. Learn more at https://www.rpoassociation.org/

    Media Contacts
    LHH Public Relations
    PR@lhh.com

    RPOA
    Lamees Abourahma, CEO
    lamees@rpoassociation.org

    The Adecco Group’s RPO business was consolidated under LHH in January 2025.

    SOURCE: LHH

    View the original press release on ACCESS Newswire

  • trueGold Gives “Memory” to Gold – Jewelry & Watches Now Tell Their Own Story

    trueGold Gives “Memory” to Gold – Jewelry & Watches Now Tell Their Own Story

    NEW YORK, NY AND SINGAPORE / ACCESS Newswire / July 23, 2025 / trueGold Consortium Pty Ltd, a subsidiary of SMX (Security Matters) PLC (NASDAQ:SMX), is revolutionizing the gold industry with chemical marking technology that creates a fully traceable and verifiable supply chain-from mining to the marketplace and, ultimately, into recycling. The system adds an invisible marker at the mine-site, records every hand-off on a secure digital ledger, and allows instant verification at any point in the metal’s life. The result is unprecedented transparency, accountability, and the confidence for brands to meet stringent ethical-sourcing standards.

    Gold has always carried emotional value; now with SMX technology, it can carry verifiable truth. The SMX technology captures the whole journey in the finished gold product itself, giving brands an authentic story to tell and consumers confidence in an ethically sourced supply chain.

    Why an Embedded Memory with the Final Product Matters

    At the gold mine and refinery, the SMX marker provides incontrovertible proof of sourcing, which can help streamline audits and regulatory filings. As the same gold moves through logistics providers, vaults, and workshops, every transfer can be both recorded digitally and verified tangibly, eliminating gaps and disputes in chain-of-custody documentation. When the metal reaches the retail brand, each finished piece would then carry a digital passport that can help substantiate ESG claims and differentiates collections in a crowded luxury market. Finally, the consumer can enjoy one-scan assurance of authenticity, recycled content, and ethical provenance-all encoded within the jewelry they wear.

    Rising Consumer Demand

    Independent studies show that more than 70 percent of shoppers are willing to pay a premium for products whose provenance is transparent and tamper-proof:

    • IBM Institute for Business Value surveyed 19,000 consumers across 28 countries and found 71 % would pay up to 37 % more for goods with full transparency and traceability.

    • PwC’s 2024 Voice of the Consumer Survey showed consumers globally willing to spend an average 9.7 % extra on sustainably sourced goods.

    The Company believes that trueGold’s application of its marking technology to watches and jewelry positions it to deliver provenance-assured pieces to discerning customers.

    Quality, Health & Safety Assured

    Recent independent testing by Intertek under the AnchorCert Pro 2 protocol on an SMX-marked 18-karat red-gold ring confirmed compliance with jewelry-safety regulations in Europe, the United States and Canada.

    The results show that SMX’s invisible marker remains chemically inert, non-toxic and undetectable in normal wear, without affecting the metal’s purity or skin compatibility. The ring satisfied all relevant EU REACH and RoHS limits, passed U.S. ASTM F2999-19 and National Stamping Act requirements, and met Canada’s Precious Metals Marking Regulations-evidence that robust traceability can coexist with the highest standards of consumer safety and product quality.

    Sources & References

    1. IBM Institute for Business Value, “Purpose and Provenance Drive Bigger Profits for Consumer Goods,” 2020 – 71 % of consumers would pay a premium for products offering full transparency and traceability.

    2. PwC, “2024 Voice of the Consumer Survey,” 2024 – Consumers are willing to spend an average 9.7 % more on sustainably sourced goods.

    3. Securing Industry, “SMX’s Subsidiary trueGold Extends its Commercial Activity to Watches and Jewelry,” 2023 – Announces expansion of trueGold’s molecular-marking technology to finished luxury products.

    4. London Bullion Market Association (LBMA), “Gold Bar Security Features,” market-standards page, accessed July 2025 – Describes accredited security features that establish a bar passport and link to the Gold Bar Integrity database

    SMX GENERAL ENQUIRIES

    Follow us through our social channel @secmattersltd

    E: info@securitymattersltd.com

    @smx.tech

    About SMX

    As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

    Forward-Looking Statements

    The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

    SOURCE: SMX (Security Matters)

    View the original press release on ACCESS Newswire

  • Adapti, Inc. (OTC: ADTI) Appoints Jeff Campbell as Executive Chairman of the Board

    Adapti, Inc. (OTC: ADTI) Appoints Jeff Campbell as Executive Chairman of the Board

    LAS VEGAS, NV / ACCESS Newswire / July 23, 2025 / Adapti, Inc. (OTC:ADTI) announced that with the completion of acquisition of the Ballengee Group, Jeff Campbell, a seasoned executive with deep experience in both social media and sports, was appointed to serve as Executive Chairman of the Board of Directors of the company. Prior to his appointment to the Board, Mr. Campbell acted as a consultant to Adapti.

    From 2019 to 2023, Mr. Campbell previously served as chief revenue officer of Fitlab, a private fitness and sports lifestyle company with an integrated fitness platform. During Mr. Campbell’s tenure, he helped grow the fitness platform to $100mm in annual recurring revenues. Prior to that, Mr. Campbell served as CEO of Geographic Farming, a digital media agency, where oversaw growth of annual revenue by 400% in under 2 years, before the agency was sold. Mr. Campbell also previously served as President of UFC Fit and early in his career, worked for sports agent, Leigh Steinberg.

    “I’m honored to join Adapti’s Board as Executive Chairman,” said Jeff Campbell. “The convergence of sports management, social media strategy, and adaptive AI-powered influencer technology represents the industry’s next frontier. I look forward to guiding Adapti on the ground floor of this evolution and helping the company achieve its full potential.”

    “To attract a seasoned executive and visionary like Jeff to serve as our Executive Chairman is a tremendous milestone for Adapti,” said Adam Nicosia, CEO of Adapti. “Jeff’s proven track record as a thought leader in media strategy-culminating in multiple successful exits-makes him uniquely qualified to help steer our Board and drive our growth strategy forward. His expertise and vision will be instrumental as we scale our integrated platform for the sports world and deliver value to our clients.”

    About Adapti, Inc. (OTC: ADTI)

    Adapti, Inc. leverages advanced AI technology to match products and brands with optimal influencers, using proprietary data analytics to drive superior marketing results. Adapti aims to build a global platform where data is an asset, efficiently paired with high-impact influencers.

    In July 2025, Adapti acquired the Ballengee Group, a full-service sports agency representing Major League Baseball athletes. The Ballengee Group assists its clients with contract negotiations, marketing deals, public relations, and strategic partnerships. The Ballengee Group has guided world champions and global icons throughout their careers.

    Adapti plans to roll out a suite of integrated services that blend traditional contract negotiation and endorsement deals with dynamic social media campaigns, which we anticipate will be powered by AdaptAI’s proprietary “data fingerprint” technology that the company is developing. This technology will utilize Large Language Models to quickly optimize and adapt to changes in the ever-evolving marketing landscape. This holistic approach is being designed to maximize engagement, drive higher ROI for brand partners, and ensure athletes capture every opportunity to grow their platforms.

    For more information, please visit our website: http://adapti.io. The information contained on our website is not incorporated by reference into this press release, and we disclaim any liability for such information.

    Forward-Looking Statements

    This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Adapti, Inc. generally identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar words. These statements are only predictions. Adapti based these forward-looking statements largely on their then-current expectations and projections about future events and financial trends as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Adapti’s control. Adapti’s actual results (including those of Ballengee post-acquisition) could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) the ability to integrate the business operations of Ballengee with that of Adapti, (ii) the ability of Adapti to timely make the necessary filings with the SEC related to the acquisition of Ballengee, and (iii) those risks detailed in Adapti’s reports filed with the SEC, as well as other documents that may be filed by Adapti from time to time with the SEC. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Additional risks and uncertainties can be found in the Company’s recent annual and quarterly reports, filed with the SEC or other filings that are filed with the SEC thereafter. Adapti cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made. Except as required by applicable law or regulation, Adapti undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.

    Investors Contact:

    Phone: 214-301-3745
    Email: investorrelations@adapti.io

    SOURCE: Adapti, Inc.

    View the original press release on ACCESS Newswire

  • Terra Innovatum SOLO(TM) Design Aligns with U.S. NRC’s Recent Considerations of Streamlined Licensing Path for Proliferation-Resistant Micro-Modular Reactors

    Terra Innovatum SOLO(TM) Design Aligns with U.S. NRC’s Recent Considerations of Streamlined Licensing Path for Proliferation-Resistant Micro-Modular Reactors

    SOLO™’s Non-Proliferation Approach Aligns with U.S. NRC’s Proposed Licensing Framework Criteria for Low Risk, Proliferation-Resistant Micro Modular Reactors

    NEW YORK, NY AND AUSTIN, TX / ACCESS Newswire / July 23, 2025 / Terra Innovatum Srl (“Terra Innovatum,” or the “Company”), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (NASDAQ:GSRT), a publicly traded special purpose acquisition company, today issued the following statement in support of the U.S. Nuclear Regulatory Commission’s (“NRC”) long-term vision for micro-modular reactor licensing, following the NRC’s public meetings on July 17-18, 2025:

    “We are encouraged by the NRC’s recent public dialogue and their proposed rulemaking regarding future streamlined licensing for micro-modular and other low risk reactors. In particular, we support the NRC’s introduction of limits on the type and quantity of proliferation materials – or ‘Special Nuclear Materials’ (SNM) such as uranium or plutonium – in its proposed fundamental entry criteria, which further validates and aligns with SOLOTM‘s Safeguards by Design approach.

    In Picture: A rendering of the SOLO™ reactor seamlessly integrated within a commercial real estate setting.

    From the earliest stages of development in 2018, we conceived our micro-modular reactor with a clear global mission: to deliver a safe, low risk, and non-proliferant nuclear energy solution suitable for deployment in diverse environments around the world. Recognizing the unique challenges associated with the use of SNM, we emphasized proliferation resistance not as an afterthought, but as a core design principle.

    Our reactor has been embedded with safeguards which aim to limit unauthorized access, diversion, or repurposing of fissile materials and align with guidance from the International Atomic Energy Agency and Department of Energy.

    SOLOTM‘s compact, sealed core design, limits SNM while incorporating a real-time core measurement to prevent the misuse of these materials. Additionally, our decision to use standard Low Enriched Uranium fuel supports international non-proliferation objectives while leveraging existing fuel infrastructure and licensing precedents.

    We commend the NRC for its transparent, inclusive approach to rulemaking and look forward to participating in the formal comment process. Terra Innovatum remains committed to working with domestic and international stakeholders to advance the responsible deployment of micro-modular reactors – and to ensuring that designs like SOLOTM continue to lead the way.”

    ABOUT TERRA INNOVATUM & SOLOTM

    Terra Innovatum’s mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 MWe at a time.

    Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.

    It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.

    SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.

    To learn more, visit: www.terrainnovatum.com.

    CONTACTS

    Giordano Morichi
    Partner, Chief Business Development Officer & Investor Relations
    Terra Innovatum Srl
    E: g.morichi@terrainnovatum.com
    W: www.terrainnovatum.com

    Nicholas Hresko-Staab
    Vice President
    Investor & Media Relations
    Alliance Advisors IR
    E: TerraIR@allianceadvisors.com

    IMPORTANT INFORMATION FOR SHAREHOLDERS

    This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.

    In connection with the business combination, a Dutch public limited liability company (“Pubco”), GSR III Acquisition Corp. (“GSRT”) and Terra Innovatum s.r.l. (“Terra Innovatum” and, together with GSR III and Pubco, the “Registrant Parties”) have filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus of Pubco relating to the offer of securities to be issued in connection with the business combination, and a preliminary proxy statement of GSRT to be distributed to holders of GSRT’s ordinary shares in connection with GSRT’s solicitation of proxies for a vote by GSRT’s shareholders with respect to the Business Combination and other matters described in the Registration Statement. The Registrant Parties also plan to file other documents with the SEC regarding the business combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to the shareholders of GSRT. INVESTORS OF THE REGISTRANT PARTIES ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS RELATING TO THE BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.

    Investors will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about the Registrant Parties once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by GSRT may be obtained free of charge by written request to GSRT at 5900 Balcones Drive, Suite 100, Austin TX 78731.

    PARTICIPANTS IN THE SOLICITATION

    Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT’s filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

    FORWARD LOOKING STATEMENTS

    The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

    The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC’s declaration of the effectiveness of the Registration Statement (which will include the proxy statement/prospectus contained therein) to be filed by the Registrant Parties or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination,

    which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT’s other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.

    None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.

    In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to

    update or revise any forward-looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.

    SOURCE: TERRA INNOVATUM SRL

    View the original press release on ACCESS Newswire

  • Retired But Owe Back Taxes? Clear Start Tax Warns About Required Minimum Distributions (RMDs) Fueling IRS Debt

    Retired But Owe Back Taxes? Clear Start Tax Warns About Required Minimum Distributions (RMDs) Fueling IRS Debt

    Seniors are often surprised by taxes on mandatory withdrawals – Clear Start Tax explains how RMDs can increase IRS balances in retirement.

    IRVINE, CA / ACCESS Newswire / July 23, 2025 / Many retirees assume their tax worries end with their final paycheck, but Required Minimum Distributions (RMDs) are catching them off guard. According to Clear Start Tax, mandatory withdrawals from retirement accounts like 401(k)s and traditional IRAs are pushing thousands of seniors into higher tax brackets – and in many cases, deeper IRS debt.

    “RMDs aren’t optional, and neither are the taxes they create,” said the Head of Client Solutions at Clear Start Tax. “We see clients who’ve paid off their homes, receive Social Security, and still end up owing thousands to the IRS just because they didn’t plan for the tax hit.”

    How RMDs Can Trigger IRS Debt

    Once a taxpayer turns 73 (as of 2025), the IRS requires them to begin withdrawing a calculated amount each year from qualified retirement accounts. These distributions are taxed as ordinary income, even if the funds are not spent.

    Clear Start Tax outlines several ways RMDs can create or increase back taxes:

    • Unexpected Withholding Gaps – Many custodians don’t withhold enough to cover the tax burden.

    • Combined Income Penalties – RMDs added to Social Security and pensions can push retirees into higher tax brackets.

    • Loss of Tax Credits – Increased income can disqualify seniors from deductions, credits, or affordable health plans.

    • Missed Payments – Seniors on fixed incomes may not make estimated tax payments, causing interest and penalties to build.

    “RMDs aren’t just income – they can tip the scales, especially when combined with unfiled returns or prior IRS debt,” added the Head of Client Solutions. “And since they’re required by law, you can’t just opt out.”

    Why Retirees Often Miss the Warning Signs

    Clear Start Tax notes that many seniors don’t realize their tax situation has changed. Without a W-2 or employer, there’s often no system in place for regular withholding, and no alert until a CP14 notice or lien arrives.

    Additionally, seniors withdrawing from multiple accounts may fail to track their total taxable income. A small oversight can lead to large consequences.

    What Seniors Can Do to Avoid RMD-Related Debt

    Many retirees aren’t aware that Required Minimum Distributions (RMDs) are fully taxable, and skipping tax planning can lead to debt quickly. Clear Start Tax urges seniors to treat RMDs like any other income source and take proactive steps before tax time.

    Clear Start Tax recommends:

    • Review all retirement account distributions annually

    • Adjust withholdings to better match tax liability

    • Use IRS Form 1040-ES for quarterly estimated payments

    • Recalculate tax strategy each year based on age, income, and filing status

    • File missing returns before enforcement escalates

    Fresh Start Program Offers Relief for Retirees

    If tax debt has already built up – whether from unplanned RMD taxes or previous underpayment – retirees may still have viable relief options. Clear Start Tax helps seniors use IRS Fresh Start programs to resolve debt without jeopardizing essential income or retirement assets.

    Clear Start Tax helps qualifying retirees:

    • Apply for payment plans based on current income and expenses

    • Submit Offers in Compromise to reduce the total amount owed

    • Request penalty abatement for first-time or hardship-related cases

    • Regain filing compliance to avoid enforcement actions or levies

    • Protect Social Security income from garnishment, where applicable

    By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.

    About Clear Start Tax

    Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

    Need Help With Back Taxes?

    Click the link below:
    https://clearstarttax.com/qualifytoday/
    (888) 710-3533

    Contact Information

    Clear Start Tax
    Corporate Communications Department
    seo@clearstarttax.com
    (949) 535-1627

    SOURCE: Clear Start Tax

    View the original press release on ACCESS Newswire

  • Avel eCare Appoints Martainn Lenhardt as Chief Financial Officer to Lead Financial Strategy Amid Rapid Growth and Innovation

    Avel eCare Appoints Martainn Lenhardt as Chief Financial Officer to Lead Financial Strategy Amid Rapid Growth and Innovation

    SIOUX FALLS, SD / ACCESS Newswire / July 23, 2025 / Avel eCare, a leading provider of telemedicine services in the United States, today announced the appointment of Martainn Lenhardt as Chief Financial Officer (CFO). Lenhardt brings over 20 years of healthcare finance experience to the role, where he will oversee Avel’s financial strategy, operations, and performance during a pivotal era of innovation and nationwide expansion.

    Lenhardt joins Avel eCare following his tenure as VP of Finance at Lyric and senior leadership roles at Change Healthcare, where he managed a $480 million business unit and was instrumental in driving growth and improving margins. He is widely recognized for his expertise in strategic growth, mergers and acquisitions, and optimizing global operations. His ability to turn complexity into opportunity and build agile, purpose-driven teams will be instrumental in advancing Avel’s mission.

    “Avel eCare is transforming how healthcare is delivered across the country,” said Lenhardt. “It’s an honor to join this team and help scale a model that brings high-quality, virtual care to every corner of the nation.”

    This appointment comes at a time of unprecedented momentum for Avel eCare. In the past two years alone, Avel has launched new service lines, secured exclusive partnerships with organizations like Amwell and Cibolo Health, and expanded services to more than 46 states. The company continues to innovate with in-ambulance telehealth, ICU solutions, and programs that support EMS, law enforcement, and correctional health, making care more accessible, cost-effective, and consistent, especially in rural and underserved areas.

    The new CFO joins an accomplished executive team committed to advancing healthcare access and outcomes across the country. Avel’s leadership includes:

    • Doug Duskin – Chief Executive Officer

    • Don Yish – Chief Revenue Officer

    • Jay Weems – Chief Operations Officer

    • Kelly Rhone, MD – Chief Medical Officer

    • Robert Spurlock – Chief Information Officer

    About Avel eCare
    Avel eCare is a national leader in technology-enabled clinical services delivered through telemedicine, offering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel’s board-certified clinicians partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it’s needed most. Learn more at: www.avelecare.com

    Media Contact:
    Jessica Gaikowski
    Avel eCare
    media@avelecare.com

    SOURCE: Avel eCare

    View the original press release on ACCESS Newswire